Résumé
Objective: To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.Methods: RA patients from 15 registries in the JAK‐pot collaboration were included. MACE incidence was analysed using two approaches: a within‐registry analysis aggregating country‐specific estimates from registers with >25 incident MACE events through meta‐analysis, and an individual‐level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRR) of MACE between treatment groups, accounting for multiple treatment courses.Results The study included 73’008 treatment courses (16’417 JAKi, 35’373 TNFi and 21’218 bDMARD‐OMA) and 828 incident MACE among 51’233 patients. Median follow‐up time was 1.3 years, with most of the follow‐up concentrated in the first two years of treatment. Incidence rates were 7.0, 7.6 and 11.8 per 1’000 person‐years for JAKi, TNFi and bDMARD‐OMA, respectively. Compared to TNFi, JAKi (within‐registry adjusted IRR: 0.89, 95%CI 0.63 to 1.25)) had similar incidence rates of MACE and bDMARD‐OMA had higher rates (within‐registry adjusted IRR: 1.35, 95%CI 1.10 to 1.66). Combined analysis showed similar results.Conclusion Observational data from the JAK‐pot collaboration show no evidence of an increase in cardiovascular events during the first 2 years of use with JAKi compared to TNFi in the general RA population.